The significant jump in June quarter net profit was on account of robust sales and income received from biopharmaceutical firm Boehringer Ingelheim for achieving key milestones for its novel MEK inhibitor compound collaboration.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3xISVIc
via IFTTT
0 comments:
Post a Comment